ClinicalTrials.gg
SuspendedNCT06952816Updated Nov 18, 2026

Automated Oxygen Titration With the EMILY.AI Device in a Respiratory Intermediate Care Unit

An interventional study of Emily.AI and Manual oxygen titration in Chronic Respiratory Failure, Acute Respiratory Failure and Hypoxemic Respiratory Failure, sponsored by Aether Tech S.L.. Suspended at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Aether Tech S.L. · Not applicable, Interventional, and Treatment

How we know

Why this study was suspended
Recruitment temporarily paused pending competent authority (AEMPS) approval of a protocol amendment. Recruitment will resume after approval. Not stopped for safety reasons.
Updated Nov 2, 2026Now SuspendedStart date moved+10 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Respiratory Insufficiency with a site in Spain — 11 open to participants now, 15 under way, none of them phase 3. Respiratory Insufficiency · Spain.

Planned enrollment
23rd of 38
80 · median 116
Started
2025
with 4 others
No phase
26 of 69
5 open now
Registered
57th of 69
by date

Among the 69 studies in Respiratory Insufficiency with a site in Spain, this one is the 23rd largest by planned enrollment of the 38 interventional ones that give a count, is one of 5 that started in 2025, is one of 26 with no phase, and was the 57th registered.

Respiratory Insufficiency

1,371 studies on the registry are indexed under Respiratory Insufficiency; 266 are open to participants now.

Browse Respiratory Insufficiency studies →

Open to participants now

11 of the 69 studies in Respiratory Insufficiency with a site in Spain are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Respiratory Insufficiency with a site in Spain, or all of them as a file.
02

Study summary

This study evaluates EMILY.AI, an investigational (non-CE-marked) smart oxygen valve that automatically adjusts the oxygen flow delivered to a patient.

Adults with acute respiratory failure admitted to the Respiratory Intermediate Care Unit (RICU) of Hospital Universitario Fundación Jiménez Díaz (Madrid, Spain) receive oxygen titrated automatically by EMILY.AI and, in the same monitoring session, oxygen titrated manually by the nursing team while the device records saturation and flow.

The study measures how much of the time patients stay within their target saturation range under each method, how fast the device corrects deviations, the alerts it generates, nursing workload, oxygen use and patient comfort. This substudy is part of clinical investigation FJD-EMILY-23-02, whose other substudies are registered in separate records.

Read the detailed description

Background Oxygen therapy is usually titrated manually. Both hypoxaemia and hyperoxaemia are associated with harm, so keeping patients within a target SpO2 range matters. EMILY.AI combines a medical-grade oxygen valve with rule-based algorithm that sets the oxygen flow from SpO2, heart rate and respiratory rate, with continuous logging of physiological signals, delivered flow and algorithm-recommended flow.

Setting and supervision All sessions take place in the RICU of Hospital Universitario Fundación Jiménez Díaz under continuous supervision by a study physician, with conventional oxygen therapy available as back-up. Patients are classified at inclusion as hypoxaemic (PaCO2 ≤45 mmHg; target SpO2 94-98%) or hypercapnic (PaCO2 >45 mmHg; target SpO2 92-94%). The same patient may take part in more than one session on different days if their oxygen requirement has changed.

Study phases

The substudy has been conducted in successive phases under amendments approved by the Ethics Committee and the Spanish Agency of Medicines and Medical Devices (AEMPS):

  1. Initial phase (April-August 2025 and December 2025, CIP v3.0-v5.0): EMILY.AI titrated oxygen in closed-loop mode under physician supervision, without a paired manual-control period.
  2. Paired phase (January-April 2026, CIP v4.0 and v5.0): each session comprises approximately 5 hours of closed-loop titration by EMILY.AI followed by approximately 5 hours of manual titration by the nursing team, during which the device keeps recording but does not control the flow.
  3. Algorithm adjustment extension (June-July 2026, CIP v6.0 and v7.0): additional participants, with the same paired session, to validate a refinement of the algorithm. Analysed separately.
  4. Algorithm adjustment extension (planned, CIP v8.0): approximately 10 additional participants, with the same paired session, to validate an adjustment of the algorithm.

Participants are not told which period is automatic and which is manual. The investigators and nursing staff are not masked, for safety reasons.

The protocol FJD-EMILY-23-02 also includes substudies in a conventional hospital ward and during exercise (6-minute walk test), registered separately.

03

Conditions studied

  • Chronic Respiratory Failure
  • Acute Respiratory Failure
  • Hypoxemic Respiratory Failure
  • Hypercapnic Respiratory Failure
  • Acute-on-chronic Respiratory Failure

Keywords

  • Respiratory failure
  • Hypoxia
  • Oxigenotherapy
  • automated oxygen titration
  • Hiperoxia
  • closed-loop oxygen therapy
04

Who can participate

The criteria were revised on the registry on Oct 29, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women over 18 years of age or older.
  • Admitted to the Respiratory Intermediate Care Unit with acute respiratory failure, defined as baseline arterial PaO2 below 60 mmHg or the need for supplemental oxygen to maintain SpO2 above 90%. Patients on long-term oxygen therapy are eligible if a clinical deterioration requires a higher-than-usual oxygen flow to maintain SpO2 above 90%.
  • Spontaneous breathing without positive-pressure ventilatory support (invasive or non-invasive mechanical ventilation, or CPAP) for at least 8 consecutive hours.
  • Able to understand the study and sign .

Exclusion criteria

Exclusion Criteria:

  • Hemodynamic instability or need for vasoactive drugs.
  • Severe temperature changes (axillary temperature above 39 °C or below 35 °C).
  • Hemoglobinopathies or severe anemia ( below 7 g/dL).
  • Severe acidosis (pH below 7.20) or severe alkalosis (pH above 7.55).
  • Anatomical abnormalities preventing correct placement of the pulse oximeter.
  • Pregnancy or breastfeeding (women of require a negative pregnancy test at screening).
  • Oxygen flow requirement exceeding the valve capacity (more than 40 L/min).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
Single (Participant)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Paired phase: closed-loop then manual titration

    Participants enrolled January-April 2026 (CIP v4.0-v5.0). Same session: \~5 h closed-loop titration by EMILY.AI, then \~5 h manual titration by nursing staff with the device recording only.

    Device: Emily.AI · Other: Manual oxygen titration

  • Experimental
    Extension: adjusted control parameters (slow controller)

    Participants enrolled June-July 2026 (CIP v6.0). Same paired session, with refined algorithm parameters.

    Device: Emily.AI · Other: Manual oxygen titration

  • Experimental
    Extension: adjusted minimum-flow parameter

    Approximately 10 participants (CIP v8.0). Same paired session, with an adjusted parameter.

    Device: Emily.AI · Other: Manual oxygen titration

  • Experimental
    Initial phase: closed-loop only

    Participants enrolled April-August 2025 and December 2025 (CIP v3.0-v5.0). EMILY.AI titrates oxygen in closed-loop mode under continuous physician supervision; no paired manual period.

    Device: Emily.AI

Interventions

  • DeviceEmily.AI

    Investigational smart oxygen valve with a rule-based algorithm that adjusts oxygen flow to keep SpO2 within a target range. Other names: EMILY.AI Smart Valve

  • OtherManual oxygen titration

    Standard care: oxygen flow set and adjusted by the unit's nursing team according to usual practice. The EMILY.AI device stays connected and records signals and flow but does not control delivery.

06

What researchers measure

Primary outcomes

  1. EFFICACY - EVALUATION OF THE RATE THE DEVICE MAINTAINS BLOOD OXYGEN SATURATION LEVELS

    Percentage of monitored time with SpO2, measured by pulse oximetry, within the predefined target range (hypoxaemic patients 94-98%; hypercapnic patients 92-94%), without delivering less or more oxygen than required. Compared between the closed-loop period (EMILY.AI) and the manual titration period in the same participant.

    Time frame: During the monitoring session: approximately 5 hours of closed-loop titration followed by approximately 5 hours of manual titration on the same day (closed-loop period only in the initial phase).

Secondary outcomes

  1. ACCURACY - MEASUREMENT OF THE SYSTEM'S ACTION SPEED CORRECTING THE OXYGEN SATURATION LEVELS

    Time in seconds from 1) detection of SpO2 outside the target range to the start of correction and 2) the return of SpO2 to the target range.

    Time frame: During the monitoring session: approximately 5 hours of closed-loop titration followed by approximately 5 hours of manual titration on the same day (closed-loop period only in the initial phase).

  2. ALERT SYSTEM - MEASUREMENT OF THE NUMBER OF SYSTEM ALERTS

    Number of alerts generated by EMILY.AI for changes in the oxygen saturation of monitored patients.

    Time frame: During the monitoring session: approximately 5 hours of closed-loop titration followed by approximately 5 hours of manual titration on the same day (closed-loop period only in the initial phase).

  3. ALERT SYSTEM - EVALUATION OF THE AUTHENTICITY OF THE SYSTEM ALERTS BY COMPARING THE OXYGEN SATURATION LEVELS WITH A CONVENTIONAL SYSTEM

    Proportion of alerts confirmed by the conventional monitor and, in case of discrepancy, by arterial blood gas analysis.

    Time frame: During the monitoring session: approximately 5 hours of closed-loop titration followed by approximately 5 hours of manual titration on the same day (closed-loop period only in the initial phase).

  4. EFFICIENCY - MEASUREMENT OF THE NUMBER OF TIMES THE MEDICAL AND NURSING TEAM MUST ADJUST THE OXYGENATION

    Number of nursing or medical interventions to adjust oxygen flow or address oxygenation-related symptoms, compared between the closed-loop and manual periods.

    Time frame: During the monitoring session: approximately 5 hours of closed-loop titration followed by approximately 5 hours of manual titration on the same day (closed-loop period only in the initial phase).

  5. VERSATILITY - COMPARISON OF BLOOD OXYGEN SATURATION LEVELS MAINTENANCE BETWEEN DIFFERENT PROFILES AND SITUATIONS

    Percentage of time within the target range compared between hypoxaemic and hypercapnic participants and across clinical situations (bed rest, sitting, eating, physiotherapy).

    Time frame: During the monitoring session: approximately 5 hours of closed-loop titration followed by approximately 5 hours of manual titration on the same day (closed-loop period only in the initial phase).

  6. SAFETY - TIME WITH OXYGEN SATURATION BELOW AND ABOVE THE TARGET RANGE

    Percentage of monitored time with SpO2 below and above the target range, as indicators of insufficient or excessive oxygen delivery, compared between periods.

    Time frame: During the monitoring session: approximately 5 hours of closed-loop titration followed by approximately 5 hours of manual titration on the same day (closed-loop period only in the initial phase).

  7. EFFICIENCY - OXYGEN FLOW DELIVERED

    Mean delivered oxygen flow (L/min), distinguishing flow delivered while SpO2 was above the target range, compared between periods.

    Time frame: During the monitoring session: approximately 5 hours of closed-loop titration followed by approximately 5 hours of manual titration on the same day (closed-loop period only in the initial phase).

  8. CLINICAL BENEFIT - DYSPNOEA, ACTIVITY TOLERANCE, COMFORT AND SATISFACTION

    Participant-reported dyspnoea and tolerance during hygiene, meals and physiotherapy, comfort and satisfaction, measured with Likert-scale questionnaires.

    Time frame: During the monitoring session: approximately 5 hours of closed-loop titration followed by approximately 5 hours of manual titration on the same day (closed-loop period only in the initial phase).

  9. ADAPTABILITY - AGREEMENT BETWEEN PULSE OXIMETER MODELS

    Agreement of SpO2 measurements and trends between pulse oximeter models (Nonin, Masimo, Nihon Kohden); acceptable when variability is below 10% and does not affect patient management.

    Time frame: During the monitoring session: approximately 5 hours of closed-loop titration followed by approximately 5 hours of manual titration on the same day (closed-loop period only in the initial phase).

07

Study locations

1 site
  • Hospital Universitario Fundación Jiménez Díaz
    Madrid, Spain
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Apr 2025 (actual). Primary completion is estimated for Mar 2027, 23 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Jun 2025 → Mar 2027 and completion Dec 2026 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2025
First posted
May 1, 2025
StartActual
Apr 15, 2025
Primary completionEst.
Mar 30, 2027was Jun 2025
CompletionEst.
Mar 30, 2027was Dec 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Suspended Recruitment temporarily paused pending competent authority (AEMPS) approval of a protocol amendment. Recruitment will resume after approval. Not stopped for safety reasons.
changed Nov 2, 2026
Sites
1 site removed
Show 1 removed
  • Hospital Universitario Fundación Jiménez Díaz · Madrid, Spain
Oct 29, 2026
Start date
Apr 23, 2025→Apr 15, 2025
moved 2 times, Oct 29, 2026 – Nov 2, 2026
Primary completion
Jun 30, 2025→Mar 30, 2027
Oct 29, 2026
Study completion
Dec 30, 2026→Mar 30, 2027
Oct 29, 2026
Enrollment
20→80
Nov 2, 2026
Eligibility
1 inclusion criterion edited, 3 added, 2 removed; 1 exclusion criterion edited, 6 added, 4 removed
What changed in the criteria
Inclusion criteria
  • EditedMen and women over 18 years of age or older.
  • RemovedAdmitted to intermediate respiratory care unit with a diagnosis of acute respiratory failure for at least 8 hours.
  • RemovedInformed consent understood and signed.
  • AddedAdmitted to the Respiratory Intermediate Care Unit with acute respiratory failure, defined as baseline arterial PaO2 below 60 mmHg or the need for supplemental oxygen to maintain SpO2 above 90%. Patients on long-term oxygen therapy are eligible if a clinical deterioration requires a higher-than-usual oxygen flow to maintain SpO2 above 90%.
  • AddedSpontaneous breathing without positive-pressure ventilatory support (invasive or non-invasive mechanical ventilation, or CPAP) for at least 8 consecutive hours.
  • AddedAble to understand the study and sign informed consent.
Exclusion criteria
  • EditedHemodynamic instability or need for vasoactive drugs.
  • RemovedSevere temperature changes.
  • RemovedHemoglobinopathies, severe anemia, severe acidosis, or severe alkalosis.
  • RemovedAnatomical disturbances.
  • RemovedPregnancy or breastfeeding.
  • AddedSevere temperature changes (axillary temperature above 39 °C or below 35 °C).
  • AddedHemoglobinopathies or severe anemia (hemoglobin below 7 g/dL).
  • AddedSevere acidosis (pH below 7.20) or severe alkalosis (pH above 7.55).
  • AddedAnatomical abnormalities preventing correct placement of the pulse oximeter.
  • AddedPregnancy or breastfeeding (women of childbearing potential require a negative pregnancy test at screening).
  • AddedOxygen flow requirement exceeding the valve capacity (more than 40 L/min).
Oct 29, 2026
Interventions
Added Manual oxygen titration. Arms added: Paired phase: closed-loop then manual titration·Extension: adjusted control parameters (slow controller)·Extension: adjusted minimum-flow parameter·Initial phase: closed-loop only; arms removed: Patients with respiratory failure
across 2 updates, Oct 29, 2026 – Nov 2, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameEFFICACY - EVALUATION OF THE RATE THE DEVICE MAINTAINS BLOOD OXYGEN SATURATION LEVELSFrom enrollment to the end of treatment at 8 hours. → During the monitoring session: approximately 5 hours of closed-loop titration followed by approximately 5 hours of manual titration on the same day (closed-loop period only in the initial phase).
  • DescriptionEFFICACY - EVALUATION OF THE RATE THE DEVICE MAINTAINS BLOOD OXYGEN SATURATION LEVELS: how it is measured was reworded
Oct 29, 2026
Secondary outcomes
5 time frame changed, 4 added, 5 description edited
What changed in the outcomes
  • AddedSAFETY - TIME WITH OXYGEN SATURATION BELOW AND ABOVE THE TARGET RANGETime frame: During the monitoring session: approximately 5 hours of closed-loop titration followed by approximately 5 hours of manual titration on the same day (closed-loop period only in the initial phase).
  • AddedEFFICIENCY - OXYGEN FLOW DELIVEREDTime frame: During the monitoring session: approximately 5 hours of closed-loop titration followed by approximately 5 hours of manual titration on the same day (closed-loop period only in the initial phase).
  • AddedCLINICAL BENEFIT - DYSPNOEA, ACTIVITY TOLERANCE, COMFORT AND SATISFACTIONTime frame: During the monitoring session: approximately 5 hours of closed-loop titration followed by approximately 5 hours of manual titration on the same day (closed-loop period only in the initial phase).
  • AddedADAPTABILITY - AGREEMENT BETWEEN PULSE OXIMETER MODELSTime frame: During the monitoring session: approximately 5 hours of closed-loop titration followed by approximately 5 hours of manual titration on the same day (closed-loop period only in the initial phase).
  • Time frameACCURACY - MEASUREMENT OF THE SYSTEM'S ACTION SPEED CORRECTING THE OXYGEN SATURATION LEVELSFrom enrollment to the end of treatment at 8 hours. → During the monitoring session: approximately 5 hours of closed-loop titration followed by approximately 5 hours of manual titration on the same day (closed-loop period only in the initial phase).
  • Time frameALERT SYSTEM - MEASUREMENT OF THE NUMBER OF SYSTEM ALERTSFrom enrollment to the end of treatment at 8 hours. → During the monitoring session: approximately 5 hours of closed-loop titration followed by approximately 5 hours of manual titration on the same day (closed-loop period only in the initial phase).
  • Time frameALERT SYSTEM - EVALUATION OF THE AUTHENTICITY OF THE SYSTEM ALERTS BY COMPARING THE OXYGEN SATURATION LEVELS WITH A CONVENTIONAL SYSTEMFrom enrollment to the end of treatment at 8 hours. → During the monitoring session: approximately 5 hours of closed-loop titration followed by approximately 5 hours of manual titration on the same day (closed-loop period only in the initial phase).
  • Time frameEFFICIENCY - MEASUREMENT OF THE NUMBER OF TIMES THE MEDICAL AND NURSING TEAM MUST ADJUST THE OXYGENATIONFrom enrollment to the end of treatment at 8 hours. → During the monitoring session: approximately 5 hours of closed-loop titration followed by approximately 5 hours of manual titration on the same day (closed-loop period only in the initial phase).
  • Time frameVERSATILITY - COMPARISON OF BLOOD OXYGEN SATURATION LEVELS MAINTENANCE BETWEEN DIFFERENT PROFILES AND SITUATIONSFrom enrollment to the end of treatment at 8 hours. → During the monitoring session: approximately 5 hours of closed-loop titration followed by approximately 5 hours of manual titration on the same day (closed-loop period only in the initial phase).
  • DescriptionACCURACY - MEASUREMENT OF THE SYSTEM'S ACTION SPEED CORRECTING THE OXYGEN SATURATION LEVELS: how it is measured was reworded
  • DescriptionALERT SYSTEM - EVALUATION OF THE AUTHENTICITY OF THE SYSTEM ALERTS BY COMPARING THE OXYGEN SATURATION LEVELS WITH A CONVENTIONAL SYSTEM: how it is measured was reworded
  • DescriptionALERT SYSTEM - MEASUREMENT OF THE NUMBER OF SYSTEM ALERTS: how it is measured was reworded
  • DescriptionEFFICIENCY - MEASUREMENT OF THE NUMBER OF TIMES THE MEDICAL AND NURSING TEAM MUST ADJUST THE OXYGENATION: how it is measured was reworded
  • DescriptionVERSATILITY - COMPARISON OF BLOOD OXYGEN SATURATION LEVELS MAINTENANCE BETWEEN DIFFERENT PROFILES AND SITUATIONS: how it is measured was reworded
Oct 29, 2026
Contact
Study contact now listed: added S•••@fjd.es · •••4800; added a•••@fjd.es · •••4800. See the current contact
Oct 29, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Hospital Universitario Fundación Jiménez Díaz · Madrid, SpainContact added a•••@fjd.es · •••4800
Oct 29, 2026
Title
Validation Study of the EMILY AI Device in Acute and Chronic Respiratory Failure→Automated Oxygen Titration With the EMILY.AI Device in a Respiratory Intermediate Care Unit
Oct 29, 2026
Sponsor
Collaborators removed: Hospital Clinic of Barcelona
Oct 29, 2026
Show all 3 updates
  1. Nov 18, 2026
    Minor edits only
    + 3 other changes: verification date, description and arm descriptions
  2. Nov 2, 2026
    Recruiting→Suspended
    Why stopped Recruitment temporarily paused pending competent authority (AEMPS) approval of a protocol amendment. Recruitment will resume after approval. Not stopped for safety reasons.
    Start date Jan 23, 2026→Apr 15, 2025
    Enrollment 60→80
    Interventions Arms added: Initial phase: closed-loop only
    + 4 other changes: description, design details, contact details and site details
  3. Oct 29, 2026
    1 site removed
    Show 1 removed
    • Hospital Universitario Fundación Jiménez Díaz · Madrid, Spain
    Start date Apr 23, 2025→Jan 23, 2026
    Primary completion Jun 30, 2025→Mar 30, 2027
    Study completion Dec 30, 2026→Mar 30, 2027
    Enrollment 20→60
    Eligibility 1 inclusion criterion edited, 3 added, 2 removed; 1 exclusion criterion edited, 6 added, 4 removed
    What changed in the criteria
    Inclusion criteria
    • EditedMen and women over 18 years of age or older.
    • RemovedAdmitted to intermediate respiratory care unit with a diagnosis of acute respiratory failure for at least 8 hours.
    • RemovedInformed consent understood and signed.
    • AddedAdmitted to the Respiratory Intermediate Care Unit with acute respiratory failure, defined as baseline arterial PaO2 below 60 mmHg or the need for supplemental oxygen to maintain SpO2 above 90%. Patients on long-term oxygen therapy are eligible if a clinical deterioration requires a higher-than-usual oxygen flow to maintain SpO2 above 90%.
    • AddedSpontaneous breathing without positive-pressure ventilatory support (invasive or non-invasive mechanical ventilation, or CPAP) for at least 8 consecutive hours.
    • AddedAble to understand the study and sign informed consent.
    Exclusion criteria
    • EditedHemodynamic instability or need for vasoactive drugs.
    • RemovedSevere temperature changes.
    • RemovedHemoglobinopathies, severe anemia, severe acidosis, or severe alkalosis.
    • RemovedAnatomical disturbances.
    • RemovedPregnancy or breastfeeding.
    • AddedSevere temperature changes (axillary temperature above 39 °C or below 35 °C).
    • AddedHemoglobinopathies or severe anemia (hemoglobin below 7 g/dL).
    • AddedSevere acidosis (pH below 7.20) or severe alkalosis (pH above 7.55).
    • AddedAnatomical abnormalities preventing correct placement of the pulse oximeter.
    • AddedPregnancy or breastfeeding (women of childbearing potential require a negative pregnancy test at screening).
    • AddedOxygen flow requirement exceeding the valve capacity (more than 40 L/min).
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameEFFICACY - EVALUATION OF THE RATE THE DEVICE MAINTAINS BLOOD OXYGEN SATURATION LEVELSFrom enrollment to the end of treatment at 8 hours. → During the monitoring session: approximately 5 hours of closed-loop titration followed by approximately 5 hours of manual titration on the same day (closed-loop period only in the initial phase).
    • DescriptionEFFICACY - EVALUATION OF THE RATE THE DEVICE MAINTAINS BLOOD OXYGEN SATURATION LEVELS: how it is measured was reworded
    Secondary outcomes 5 time frame changed, 4 added, 5 description edited
    What changed in the outcomes
    • AddedSAFETY - TIME WITH OXYGEN SATURATION BELOW AND ABOVE THE TARGET RANGETime frame: During the monitoring session: approximately 5 hours of closed-loop titration followed by approximately 5 hours of manual titration on the same day (closed-loop period only in the initial phase).
    • AddedEFFICIENCY - OXYGEN FLOW DELIVEREDTime frame: During the monitoring session: approximately 5 hours of closed-loop titration followed by approximately 5 hours of manual titration on the same day (closed-loop period only in the initial phase).
    • AddedCLINICAL BENEFIT - DYSPNOEA, ACTIVITY TOLERANCE, COMFORT AND SATISFACTIONTime frame: During the monitoring session: approximately 5 hours of closed-loop titration followed by approximately 5 hours of manual titration on the same day (closed-loop period only in the initial phase).
    • AddedADAPTABILITY - AGREEMENT BETWEEN PULSE OXIMETER MODELSTime frame: During the monitoring session: approximately 5 hours of closed-loop titration followed by approximately 5 hours of manual titration on the same day (closed-loop period only in the initial phase).
    • Time frameACCURACY - MEASUREMENT OF THE SYSTEM'S ACTION SPEED CORRECTING THE OXYGEN SATURATION LEVELSFrom enrollment to the end of treatment at 8 hours. → During the monitoring session: approximately 5 hours of closed-loop titration followed by approximately 5 hours of manual titration on the same day (closed-loop period only in the initial phase).
    • Time frameALERT SYSTEM - MEASUREMENT OF THE NUMBER OF SYSTEM ALERTSFrom enrollment to the end of treatment at 8 hours. → During the monitoring session: approximately 5 hours of closed-loop titration followed by approximately 5 hours of manual titration on the same day (closed-loop period only in the initial phase).
    • Time frameALERT SYSTEM - EVALUATION OF THE AUTHENTICITY OF THE SYSTEM ALERTS BY COMPARING THE OXYGEN SATURATION LEVELS WITH A CONVENTIONAL SYSTEMFrom enrollment to the end of treatment at 8 hours. → During the monitoring session: approximately 5 hours of closed-loop titration followed by approximately 5 hours of manual titration on the same day (closed-loop period only in the initial phase).
    • Time frameEFFICIENCY - MEASUREMENT OF THE NUMBER OF TIMES THE MEDICAL AND NURSING TEAM MUST ADJUST THE OXYGENATIONFrom enrollment to the end of treatment at 8 hours. → During the monitoring session: approximately 5 hours of closed-loop titration followed by approximately 5 hours of manual titration on the same day (closed-loop period only in the initial phase).
    • Time frameVERSATILITY - COMPARISON OF BLOOD OXYGEN SATURATION LEVELS MAINTENANCE BETWEEN DIFFERENT PROFILES AND SITUATIONSFrom enrollment to the end of treatment at 8 hours. → During the monitoring session: approximately 5 hours of closed-loop titration followed by approximately 5 hours of manual titration on the same day (closed-loop period only in the initial phase).
    • DescriptionACCURACY - MEASUREMENT OF THE SYSTEM'S ACTION SPEED CORRECTING THE OXYGEN SATURATION LEVELS: how it is measured was reworded
    • DescriptionALERT SYSTEM - EVALUATION OF THE AUTHENTICITY OF THE SYSTEM ALERTS BY COMPARING THE OXYGEN SATURATION LEVELS WITH A CONVENTIONAL SYSTEM: how it is measured was reworded
    • DescriptionALERT SYSTEM - MEASUREMENT OF THE NUMBER OF SYSTEM ALERTS: how it is measured was reworded
    • DescriptionEFFICIENCY - MEASUREMENT OF THE NUMBER OF TIMES THE MEDICAL AND NURSING TEAM MUST ADJUST THE OXYGENATION: how it is measured was reworded
    • DescriptionVERSATILITY - COMPARISON OF BLOOD OXYGEN SATURATION LEVELS MAINTENANCE BETWEEN DIFFERENT PROFILES AND SITUATIONS: how it is measured was reworded
    Interventions Added Manual oxygen titration. Arms added: Paired phase: closed-loop then manual titration·Extension: adjusted control parameters (slow controller)·Extension: adjusted minimum-flow parameter; arms removed: Patients with respiratory failure
    Sponsor Collaborators removed: Hospital Clinic of Barcelona
    Contact Study contact now listed: added S•••@fjd.es · •••4800; added a•••@fjd.es · •••4800. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Hospital Universitario Fundación Jiménez Díaz · Madrid, SpainContact added a•••@fjd.es · •••4800
    Title Validation Study of the EMILY AI Device in Acute and Chronic Respiratory Failure→Automated Oxygen Titration With the EMILY.AI Device in a Respiratory Intermediate Care Unit
    + 4 other changes: verification date, description, conditions and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06952816
Lead sponsor
Aether Tech S.L.
Collaborators
Hospital Universitario Fundación Jiménez Díaz
Responsible party
Sponsor
First posted
May 1, 2025
Start date
Apr 15, 2025
Primary completion
Mar 30, 2027 (estimated)
Completion
Mar 30, 2027 (estimated)
Last update
Nov 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion